| Generic name | Luspatercept-aamt |
| Brand name(s), other common name(s) | Reblozyl® |
| Drug type | Erythroid maturation agent |
| How the drug is given | Injection, for subcutaneous use |
Indications and Usage
Luspatercept-aamt is FDA approved for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Side effects needing medical attention
The most common adverse reactions were fatigue, headache, musculoskeletal pain, pain in a joint (arthralgia), dizziness/vertigo, nausea, diarrhea, cough, abdominal pain, difficulty breathing (dyspnea), and hypersensitivity.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.